Back

Trial discontinued. This compound has not appeared in active U.S. clinical trials for some time and may have been withdrawn or abandoned. Existing favourites and notes are preserved for historical reference.

Enicepatide

PipelinePhase 2PeptideInvestigational

Sponsors:: Carmot Therapeutics, Inc., Hoffmann-La Roche
Active US trials:: 1
Earliest primary completion:: May 29, 2026

👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

Similar Products

Saxenda

INVOKAMET

Jardiance

OZEMPIC

Synopsis

Generated with AlphaAI

Product:

Enicepatide

Category:

Indication:

Mechanism:

Safety:

Dosing:

Patient:

Reviews:

No reviews yet

Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (1)

NCT	Phase	Status	Sponsor	Primary Completion
NCT06628362	Phase 2	ACTIVE_NOT_RECRUITING	Carmot Therapeutics, Inc.	May 29, 2026

About this drug

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Enicepatide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers